Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.
Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.
StrongSupportsmedium confidence
Use of GLP-1RAs in IBD patients was not associated with an increased risk of corticosteroid use (OR: 0.93; 95% CI: 0.17-5.16; I2 = 11.4%) compared to non-GLP-1 users.
Why this rating
Based on a meta-analysis of observational studies.
Source
Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis
Noppachai Siranart et al. · Journal of Crohn s and Colitis · 2025
DOI 10.1093/ecco-jcc/jjaf193
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →